Neurogene Inc (NGNE)
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological disorders. Its pipeline includes NGN-401, an adeno-associated virus 9-based candidate being studied in a Phase 1/2 trial for Rett syndrome, and NGN-101, a gene therapy program in a Phase 1/2 trial for CLN5 Batten disease. The company has licensing agreements with the University of Edinburgh, Virovek, Sigma-Aldrich, and Stanford University. Neurogene was founded in 2018 and is based in New York, New York. Neurogene common stock trades on the NASDAQ under the symbol NGNE.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NGNE
|
$34.39
|
-6.8% Downside
|
Fair
|
$81.71
|
121.5% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-7.5x
|
3.1x
|
—
|
744.1 M
|
501.1 M
|
1.2%
|
55.9%
|
15.2
|
—
|
84.4%
|
